GB201102237D0 - Particle formulation - Google Patents
Particle formulationInfo
- Publication number
- GB201102237D0 GB201102237D0 GBGB1102237.3A GB201102237A GB201102237D0 GB 201102237 D0 GB201102237 D0 GB 201102237D0 GB 201102237 A GB201102237 A GB 201102237A GB 201102237 D0 GB201102237 D0 GB 201102237D0
- Authority
- GB
- United Kingdom
- Prior art keywords
- particle formulation
- formulation
- particle
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1102237.3A GB201102237D0 (en) | 2011-02-09 | 2011-02-09 | Particle formulation |
PCT/GB2012/050283 WO2012107765A2 (en) | 2011-02-09 | 2012-02-09 | Particle formulation |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB1102237.3A GB201102237D0 (en) | 2011-02-09 | 2011-02-09 | Particle formulation |
Publications (1)
Publication Number | Publication Date |
---|---|
GB201102237D0 true GB201102237D0 (en) | 2011-03-23 |
Family
ID=43836446
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
GBGB1102237.3A Ceased GB201102237D0 (en) | 2011-02-09 | 2011-02-09 | Particle formulation |
Country Status (2)
Country | Link |
---|---|
GB (1) | GB201102237D0 (en) |
WO (1) | WO2012107765A2 (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8765725B2 (en) | 2012-05-08 | 2014-07-01 | Aciex Therapeutics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
CN107880091B (en) | 2012-05-08 | 2020-12-18 | 尼科斯眼药公司 | Formulations of hydrophobic therapeutic agents, methods of making and uses thereof |
US9757395B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9757529B2 (en) | 2012-12-20 | 2017-09-12 | Otitopic Inc. | Dry powder inhaler and methods of use |
US9815865B2 (en) | 2013-01-07 | 2017-11-14 | Nicox Ophthalmics, Inc. | Preparations of hydrophobic therapeutic agents, methods of manufacture and use thereof |
CA2910766C (en) | 2013-04-30 | 2020-12-15 | Otitopic Inc. | Dry powder formulations and methods of use |
US9993488B2 (en) | 2014-02-20 | 2018-06-12 | Otitopic Inc. | Dry powder formulations for inhalation |
AU2015296142A1 (en) * | 2014-07-31 | 2017-02-23 | Otitopic Inc. | Dry powder formulations for inhalation |
US10517828B2 (en) * | 2014-10-08 | 2019-12-31 | Zambon S.P.A. | Composition comprising at least one dry powder obtained by spray drying to increase the stability of the formulation |
DE102016218604A1 (en) | 2016-09-27 | 2018-03-29 | Constantin Adams | A particulate mixture, preferably for use in the prophylaxis and / or treatment of an airway disorder |
WO2019059953A2 (en) | 2017-09-22 | 2019-03-28 | Otitopic Inc. | Dry powder compositions with magnesium stearate |
US10786456B2 (en) | 2017-09-22 | 2020-09-29 | Otitopic Inc. | Inhaled aspirin and magnesium to treat inflammation |
WO2021216710A1 (en) * | 2020-04-24 | 2021-10-28 | The Medical College Of Wisconsin, Inc. | Use of salmeterol as an anti-coronaviral agent |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP3732508B2 (en) | 1993-10-01 | 2006-01-05 | アストラ・アクチエボラーグ | Method for producing powdered drug |
US7521068B2 (en) * | 1998-11-12 | 2009-04-21 | Elan Pharma International Ltd. | Dry powder aerosols of nanoparticulate drugs |
FI20002215A0 (en) * | 2000-10-06 | 2000-10-06 | Orion Yhtymae Oyj | Combination Particles |
US7572430B2 (en) | 2000-11-09 | 2009-08-11 | Cyprus Amax Minerals Company | Method for producing nano-particles |
GB0516549D0 (en) | 2005-08-12 | 2005-09-21 | Sulaiman Brian | Milling system |
EA015999B1 (en) | 2006-10-24 | 2012-01-30 | Бенек Ой | Device for producing nanoparticles |
EP2050437A1 (en) * | 2007-10-15 | 2009-04-22 | Laboratoires SMB | Improved pharmaceutical dry powder compositions for inhalation. |
-
2011
- 2011-02-09 GB GBGB1102237.3A patent/GB201102237D0/en not_active Ceased
-
2012
- 2012-02-09 WO PCT/GB2012/050283 patent/WO2012107765A2/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
WO2012107765A3 (en) | 2012-11-15 |
WO2012107765A2 (en) | 2012-08-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ZA201306391B (en) | Nanoparticle compositions | |
GB201111438D0 (en) | Formulation | |
GB201102237D0 (en) | Particle formulation | |
HK1211862A1 (en) | Nanoparticle formulation | |
ZA201309221B (en) | Formulation | |
EP2699670A4 (en) | Cell-synthesized particles | |
EP2755020A4 (en) | Particle detector | |
HK1202445A1 (en) | New formulation | |
PL2380962T3 (en) | Particle | |
PL2701506T3 (en) | Formulation component | |
GB201111775D0 (en) | Compounds and uses thereof | |
EP2867303A4 (en) | Silsesquioxane-like particles | |
ZA201402456B (en) | Formulation | |
GB201121377D0 (en) | Formulation component | |
HK1201685A1 (en) | Pazopanib formulation | |
IL229106A (en) | Encapsulated particle | |
PL2584028T3 (en) | Particle | |
GB201107039D0 (en) | Formulation component | |
HUE037814T2 (en) | Formulation component | |
GB201110278D0 (en) | Formulations | |
HK1208689A1 (en) | Particle size reduction | |
GB201106958D0 (en) | Formulation | |
GB2496656B (en) | Film-Forming Formulation | |
GB201104284D0 (en) | Formulation | |
ZA201308107B (en) | Spread |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AT | Applications terminated before publication under section 16(1) |